GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » EV-to-EBITDA

Oculis Holding AG (Oculis Holding AG) EV-to-EBITDA : -6.18 (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oculis Holding AG's enterprise value is $406.79 Mil. Oculis Holding AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-65.78 Mil. Therefore, Oculis Holding AG's EV-to-EBITDA for today is -6.18.

The historical rank and industry rank for Oculis Holding AG's EV-to-EBITDA or its related term are showing as below:

OCS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.59   Med: 0   Max: 0
Current: -6.18

OCS's EV-to-EBITDA is ranked worse than
100% of 450 companies
in the Biotechnology industry
Industry Median: 9.57 vs OCS: -6.18

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Oculis Holding AG's stock price is $11.85. Oculis Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.845. Therefore, Oculis Holding AG's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Oculis Holding AG EV-to-EBITDA Historical Data

The historical data trend for Oculis Holding AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG EV-to-EBITDA Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - - -3.04

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.21 -4.10 -3.17 -3.04 -5.37

Competitive Comparison of Oculis Holding AG's EV-to-EBITDA

For the Biotechnology subindustry, Oculis Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oculis Holding AG's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's EV-to-EBITDA falls into.



Oculis Holding AG EV-to-EBITDA Calculation

Oculis Holding AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=406.787/-65.779
=-6.18

Oculis Holding AG's current Enterprise Value is $406.79 Mil.
Oculis Holding AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG  (NAS:OCS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Oculis Holding AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=11.85/-1.845
=At Loss

Oculis Holding AG's share price for today is $11.85.
Oculis Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.845.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Oculis Holding AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (Oculis Holding AG) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.